YNBY International

What YNBY International does

YNBY International Limited, formerly Ban Loong Holdings, is a Hong Kong-headquartered (32/F, Kornhill Plaza, Quarry Bay) business-development platform that connects Mainland China industrial resources with overseas markets. Founded in 1971 and listed on the Hong Kong Stock Exchange since 1991 under stock code 30 HK, the company was founded by George Cho-chi and currently operates with 51-100 employees.

In 2022, YNBY executed a strategic transformation to focus on the health industry, repositioning its portfolio around four product lines: pharmaceuticals, healthcare, raw materials supply, and cosmetics. The group generates revenue across four streams: international trade, e-commerce, healthcare products, and financial investment. Its go-to-market combines B2B enterprise field sales with an e-commerce channel, and it serves two explicitly named customer segments: International Clients (overseas buyers) and Domestic Clients (Mainland China).

The operating model is that of a cross-border intermediary rather than an integrated manufacturer or branded healthcare company: YNBY does not disclose proprietary manufacturing, technology platforms, or R&D pipeline in the available data. Its value proposition rests on the combination of long-standing HKEX-listed credibility, a multi-decade sourcing presence in China, and a dual-segment client structure that links Chinese industrial supply to overseas demand across both traditional enterprise sales and digital channels.

Name

YNBY International

Legal name

YNBY International Limited

Website

https://0030hk.com

Company type

Public

Founded year

1971

Operating status

Operating

Headcount range

51–100 employees

Short description

YNBY International is a Hong Kong-listed cross-border platform linking Mainland China industrial resources with overseas buyers across pharmaceuticals, healthcare, raw materials, and cosmetics via B2B field sales and e-commerce, serving International and Domestic Clients.

Ownership category

akta.pro rank

Product category

International Health Industry Trade

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Medical, Dental & Lab Supply Marketplaces (CRAFAHAG)

Keywords

• Health industry trade
• International business development
• Pharmaceuticals distribution
• Healthcare products supply
• Cross-border commerce

Headquarters

HQ city

Wan Chai

HQ country

Hong Kong SAR China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. International Trade: Core business stream involving cross-border trade of health industry products including pharmaceuticals, healthcare products, cosmetics, and raw materials between Mainland China and overseas markets.
2. E-commerce: Digital commerce operations connecting industrial resources with markets, serving both international and domestic clients through online platform capabilities.
3. Healthcare Products: Sale of healthcare products and pharmaceuticals through product categories including pharmaceuticals, healthcare supplements, cosmetics, and raw material supply.
4. Financial Investment: Investment activities within the health industry and related sectors as part of the company's comprehensive platform approach.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

YNBY International Limited operates as a comprehensive international business development platform based in Hong Kong, bridging high-quality industrial resources in Mainland China with overseas markets. Centering on the health industry, the company engages in international trade, e-commerce, healthcare products, and financial investment, with core product categories including pharmaceuticals, healthcare products, raw materials supply, and cosmetics.

Product overview

YNBY International operates as a new-type comprehensive platform for international business development, offering four core product/service categories: Pharmaceuticals, Healthcare, Raw Materials Supply, and Cosmetics. The company serves both international and domestic clients by linking quality industrial resources in Mainland China with vast overseas markets. The portfolio is unified under the health industry focus, with additional business lines covering international trade, e-commerce, and financial investment.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceuticals
• Healthcare Products Healthcare products (healthcare supplements) offered through the international business development platform, serving both international and domestic clients.
• Raw Materials Supply Supply of raw materials linking Mainland China industrial resources with international markets as part of the company's cross-border trade operations.
• Cosmetics Cosmetic products distributed through the international business development platform for international and domestic clients.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• China Traditional Chinese Medicine Holdings: Hong Kong-listed pharmaceutical company focused on Chinese medicine formulation and distribution across domestic and international markets. Directly comparable to YNBY in being a HK-listed health-products platform with cross-border distribution scope, though at a larger scale.
• China Shineway Pharmaceutical Group: HK-listed Chinese pharmaceutical manufacturer and distributor of proprietary Chinese medicines and healthcare products. Comparable as a HK-listed small-to-mid-cap health-products company with both pharma and healthcare product offerings for international markets.
• Lotus Pharmaceuticals: Specialty pharmaceutical company focused on generic drug manufacturing and distribution in Asia and other international markets. Closely matches YNBY's positioning as a cross-border pharma/health-products distribution platform with limited scale.
• Hua Han Health Industries Holdings: Hong Kong-listed health-products company engaged in distribution and sale of healthcare supplements and pharmaceuticals in China and overseas markets. Comparable as a small-cap HK-listed health-industry platform with international distribution scope.
• Grand Pharmaceutical Group: Hong Kong-listed pharmaceutical company engaged in manufacturing and distribution of pharmaceutical preparations and healthcare products globally. Comparable to YNBY in the cross-border health-products distribution model targeting overseas markets.

Broad incumbents

• China Resources Pharmaceutical Group: One of the largest state-backed pharmaceutical distributors in China, offering pharma distribution, manufacturing, and retail pharmacy operations. Comparable as a Chinese health-products platform with cross-border reach, but operating at far greater scale than YNBY.
• Sino Biopharmaceutical Limited: Hong Kong-listed pharmaceutical and healthcare company with operations in pharma manufacturing, distribution, and biotechnology. Comparable as a HK-listed health-industry company with both pharma and healthcare product lines serving Chinese and overseas markets.
• Sinopharm Group: China's largest pharmaceutical distributor and leading healthcare conglomerate covering distribution, retail pharmacy, and manufacturing. Broadly comparable industry segment but vastly larger scale; useful benchmark for the long-run scale YNBY would need to achieve to compete in pharma distribution.
• Shanghai Pharmaceuticals Holding: Major Chinese pharmaceutical and healthcare products distributor and manufacturer with extensive domestic and international operations. Comparable in cross-border pharma distribution model but operates at a national-incumbent scale far beyond YNBY's.

Emerging players

• Alibaba Health Information Technology: HK-listed digital healthcare and pharmaceutical e-commerce platform serving Chinese consumers and pharmaceutical distribution. Comparable as a B2B/B2C health-products e-commerce platform in Hong Kong listings, though with a tech-platform orientation versus YNBY's traditional trade model.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xtwitter.com/loong_ban
• Facebookfacebook.com/profile.php?id=100080583499201
• LinkedInlinkedin.com/company/ban-loong-holdings-limited-stock-code-30-hk
• Instagraminstagram.com/banloong

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about YNBY International